Physician profile

Basem Haddad

Pulmonary Disease · Westlake, OH

NPI 1821038886

$10,649.65

in general payments reported to CMS, 2019-2025

33 companies · $7,822 in 2025

The $7,822 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

Payments by year

General payments by program year, as reported to CMS.

What the payments were for

Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.

View as a table
Payment typeAmount (2023-2025)
Honoraria$6,000.00
Food and Beverage$3,112.61
Education$400.00

Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.

Who reported paying

General payments only, as reported to CMS. Product names cover 2023-2025.

CompanyGeneral paymentsYearsTop products
Verona Pharma, INC. $6,827.85 2025 Ohtuvayre
Inspire Medical Systems, INC. $805.98 2019-2025 Inspire
Glaxosmithkline, LLC. $436.10 2023-2025 Nucala, Arexvy, Trelegy Ellipta
Genzyme Corporation $384.70 2022-2025
Horizon Therapeutics Plc $383.53 2019-2023 Krystexxa
Astrazeneca Pharmaceuticals LP $192.91 2020-2023 Fasenra, Lokelma, Farxiga
Genentech USA, INC. $191.04 2019-2021
Baxter Healthcare $175.84 2024 Hillrom - Vest System Model 105 Home Care
Boehringer Ingelheim Pharmaceuticals, INC. $159.85 2019-2025 Ofev, Stiolto Respimat, Spiriva Respimat
Amgen INC. $140.05 2024 Krystexxa, Parsabiv, Tavneos
Alexion Pharmaceuticals, INC. $101.00 2024
Insmed, INC. $92.13 2020-2025 Arikayce, Brinsupri
Regeneron Healthcare Solutions, INC. $86.85 2025 Dupixent
Sanofi-Aventis U.S. LLC $76.99 2022
Jazz Pharmaceuticals INC. $66.86 2019-2021
Show all 33 companies
CompanyGeneral paymentsYearsTop products
Mylan Specialty L.P. $64.49 2024 Yupelri
Painteq LLC $56.19 2023 Painteq
Bayer Healthcare Pharmaceuticals INC. $48.00 2023
Grifols USA, LLC $42.45 2024-2025 Prolastin-C Liquid
Abbvie INC. $41.42 2021
Zoll Services LLC (A/K/A Zoll Lifecor Corp) $38.14 2022-2024 Lifevest
Calliditas Therapeutics US INC. $36.89 2025 Tarpeyo
Novo Nordisk INC $31.63 2023-2024 Ozempic, Rybelsus
Actelion Pharmaceuticals US, INC. $23.89 2024 Opsumit
Viatris Specialty LLC $22.61 2025 Yupelri
Harmony Biosciences LLC $21.19 2020
Daiichi Sankyo INC. $18.97 2021
Pfizer INC. $18.52 2020
Advanced Respiratory, INC $14.13 2021
Janssen Pharmaceuticals, INC $14.05 2021
E.R. Squibb & Sons, L.L.C. $13.73 2024 Eliquis
Sunovion Pharmaceuticals INC. $11.92 2020
Inogen, INC. $9.75 2022

Drugs and devices associated with these payments

CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.

If you want to bring it up

Most clinicians are glad to talk about this. A respectful way in:

These are normal questions. A good clinician will welcome them.

Share this page

Payment summary

Basem Haddad

$10,649.65

in general payments reported 2019-2025

Years
2019-2025
Top company
Verona Pharma, INC.
Context
The $7,822 reported for 2025 was more than what 91% of Pulmonary Disease providers received nationally (typical 2025 total: $500).

https://glasscript.com/doctor/813392/basem-haddad

Source: CMS Open Payments, program years 2019-2025. Payments are legal and often routine.

Keep an eye on this page

Get an email when the next June refresh changes this page. No account needed.

Watch this doctor

Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.